Effects of pitavastatin treatments on the plasma Lgi3 level in the patients with dyslipidemia: A randomized crossover trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003372

Enrollment

Registered

2018-11-23

Start date

2019-02-18

Completion date

Unknown

Last updated

2021-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients who assigned to the pitavastatin treatment first group will be given the pitavastatin 4 mg qd treatment for 12 weeks after randomization, followed by wash-out period of 3 weeks and lif

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Age 20-80 years (2) Patients with intermediate or low cardiovascular risks needing the statin treatment (3) Patients with intermediate or low cardiovascular risks treating the statin treatment

Exclusion criteria

Exclusion criteria: 1) Patients without signed informed consent. 2) Patients with myopathy 3) Pregnant women or women with potential childbearing 4) Patients with diabetes 5) Patients with estabilised coronary artery disease 6) Patients with heart failure 7) Life expectancy less than 1 year

Design outcomes

Primary

Measure	Time frame
Changes in Lgi3 level	—

Secondary

Measure	Time frame
changes in Lipid profile, adiponectin, and hsCRP level	—

Countries

Korea, Republic of

Contacts

Public ContactSung-Jin Hong

Yonsei University Health System, Severance Hospital

Outcome results